Autoimmune disorders, rheumatoid arthritis, systemic inflammation, and immune dysregulation
405 articles
Only 23% met major response criteria after stronger lupus treatment. Black patients had greater initial disease burden and lower observed response.
A daily pill improved facial pigmentation in two yearlong vitiligo trials, but only about one in five patients reached the main treatment target.
A placebo-controlled trial tested low-dose naltrexone for Crohn's disease, tracking inflammation, symptoms, and safety. Results are not supplied.
In a 60-patient randomized trial, blocking knee blood vessels cut osteoarthritis pain by about half for a year, whether done with imipenem/cilastatin or microspheres.
A new review proposes that biological aging, not just birthdays, may help shape who gets systemic sclerosis, which organs are affected, and why comorbidities pile up.
A Swedish study of 13,748 MS therapy episodes finds rituximab users developed IBD far more often than users of other modern MS drugs, mostly Crohn disease.
Two phase 3 trials found fewer MS relapses with remibrutinib than teriflunomide, but long-term disability benefits remain unclear.
Early evidence suggests deep B-cell depletion may enable drug-free remission in rheumatoid arthritis, but durability and safety remain uncertain.
Long-lived plasma cells may sustain autoimmune disease despite treatment. A review weighs emerging therapies against major evidence gaps.
Cellular senescence drives vascular inflammation in giant cell arteritis. Could senolytics like fisetin and quercetin reshape treatment?
Pooled data from 1,299 SLE patients show belimumab nearly halts organ damage accrual and slashes steroid use over 8 years.
A nanoscale chromatin-mapping platform uncovers how a single noncoding variant creates a rogue DNA motif that silences a key mTOR-regulating gene, raising autoimmunity risk.
